Lexeo Therapeutics News

Lexeo Therapeutics(LXEO.US) Officer Sells US$66,093 in Common Stock

$Lexeo Therapeutics(LXEO.US)$ Officer Townsend Richard Nolan sold 5,000 shares of common stock on May 13, 2024 at an average price of $13.2186 for a total value of $66,093.Source: Announcement What is

moomoo NewsMay 14 16:52 ET

Analysts Offer Insights on Healthcare Companies: Lexeo Therapeutics, Inc. (LXEO), RAPT Therapeutics (RAPT) and Hookipa Pharma (HOOK)

TipRanksMay 14 04:40 ET

RBC Capital Remains a Buy on Lexeo Therapeutics, Inc. (LXEO)

TipRanksMay 10 06:41 ET

Lexeo Therapeutics | 10-Q: Quarterly report

Futu NewsMay 9 07:07 ET · Announcements

Express News | Lexeo Therapeutics Inc: Qtrly Net Loss Was $21.7 Mln or $0.77 per Share

ReutersMay 9 07:07 ET

Lexeo Therapeutics 1Q Research and Developement Expenses $15.7M >LXEO

Lexeo Therapeutics 1Q Research and Developement Expenses $15.7M >LXEO

Dow JonesMay 9 07:03 ET

Lexeo Therapeutics 1Q Loss/Shr 77c >LXEO

Lexeo Therapeutics 1Q Loss/Shr 77c >LXEO

Dow JonesMay 9 07:02 ET

Express News | Lexeo Therapeutics Reports First Quarter 2024 Financial Results and Operational Highlights

ReutersMay 9 07:00 ET

Lexeo Therapeutics to Participate in Upcoming Investor Conferences

NEW YORK, May 07, 2024 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (NASDAQ:LXEO), a clinical stage genetic medicine company dedicated to pioneering treatments for genetically defined cardiovascular diseases and

GlobeNewswireMay 7 07:30 ET

Buy Rating Affirmed for Lexeo Therapeutics Amid Strategic Cornell Collaboration and Promising Therapy Advancements

TipRanksApr 26 02:07 ET

Matterport, Sea Limited, Ingevity And Other Big Stocks Moving Higher On Monday

U.S. stocks were higher, with the Nasdaq Composite gaining over 100 points on Monday.Shares of Matterport, Inc. (NASDAQ:MTTR) rose sharply during Monday's session.CoStar Group, Inc. (NASDAQ:CSGP) anno

BenzingaApr 22 10:10 ET

Express News | Lexeo Therapeutics Announces In-License Agreement With Cornell University To Expedite Development Of LX2006 For Treatment Of Friedreich Ataxia Cardiomyopathy; Under Agreement, Co. Has Acquired Certain Rights1 Including Rights To Current And Future Data Ge

Moomoo 24/7Apr 22 07:32 ET

Express News | Lexeo Therapeutics: In-License Agreement With Cornell University

Moomoo 24/7Apr 22 07:31 ET

Express News | Lexeo Therapeutics Inc: Interim Readout of Combined Data Set at Multiple Doses Expected Mid-Year 2024

Moomoo 24/7Apr 22 07:30 ET

Lexeo Therapeutics Announces License Agreement to Accelerate Development of LX2006 for the Treatment of Friedreich Ataxia Cardiomyopathy

Lexeo Therapeutics, Inc. (Nasdaq: LXEO) today announced an in-license agreement with Cornell University to expedite development of the investigational gene therapy candidate LX2006 for the treatment of Friedreich ataxia (FA) cardiomyopathy.

GlobeNewswireApr 22 07:30 ET

Express News | Lexeo Therapeutics Shares Rise 3.9% After U.S. FDA Grants Fast Track Tag for Gene Therapy

Moomoo 24/7Apr 16 09:35 ET

Express News | Lexeo Therapeutics Shares Are Trading Higher After the Company Announced It Was Granted FDA Fast Track Designation for LX2006, an AAVrh.10hFXN-based Gene Therapy Candidate for the Treatment of Friedreich's Ataxia Cardiomyopathy

Moomoo 24/7Apr 16 07:37 ET

Express News | Lexeo Therapeutics Granted FDA Fast Track Designation For LX2006, AAV-Based Gene Therapy Candidate For The Treatment Of Friedreich's Ataxia Cardiomyopathy

Moomoo 24/7Apr 16 07:31 ET

Express News | Lexeo Therapeutics Granted FDA Fast Track Designation for Lx2006, an Aav-Based Gene Therapy Candidate for the Treatment of Friedreich’s Ataxia Cardiomyopathy

Moomoo 24/7Apr 16 07:30 ET

Lexeo Therapeutics Files to Sell 6.97M Shares of Common Stock for Holders

Seeking AlphaApr 9 09:02 ET